EarlySense Strengthens Position as the Leader of Early Detection of Patient Deterioration

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WALTHAM, Mass.--(BUSINESS WIRE)--EarlySense, the market leader in Proactive Patient Care Solutions™, announced today that the company has been granted three United States patents. The first, US Patent number 8,403,865, was granted for the ability of the EarlySense technology to monitor and predict congestive heart failure (CHF) and asthma attacks. The second, US Patent number 8,517,953, was granted for the technology’s ability to detect the sounds of wheezing or coughing and using these to monitor asthma, CHF or COPD patients. The third patent, 8,491,492, was granted for the technology’s personalized patient deterioration prediction and trend analysis capability. Inventors include: Dr. Zvika Shinar, Guy Meger, Dr. Daniel Lange, Yossi Gross, Avner Halperin and Itzhak Pinhas.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC